Sort
4,870 grants matching “glp 1”
Development of an M1 PAM experimental therapeutic for schizophrenia
$2,072,400P Jeffrey Conn · Vanderbilt University · U19 · FY2015 · MH
TRIP-PCI: PAR1 Pepducin-Based Interventions in Arterial Thrombosis
$2,055,805Athan Kuliopulos · Tufts Medical Center · P50 · FY2013 · HL
Silica Nanocapsule-Mediated Nonviral Delivery of CRISPR Base Editor mRNA and Allele Specific sgRNA for Gene Correction in Leber Congenital Amaurosis
$2,051,273Shaoqin - Gong · University Of Wisconsin-Madison · U19 · FY2024 · NS
Novel, Non-Opioid, Non-Addictive Intrathecal Therapy for the Treatment of Chronic Pain
$2,050,367James N Campbell · Centrexion Therapeutics Corporation · UG3 · FY2021 · NS
Novel, Non-hormonal Therapeutic for Endometriosis
$2,045,782Tanya Christineh Petrossian · Endomet Biosciences, Inc · SB1 · FY2025 · HD
Scientific Core - Compound Optimization and Prioritization.
$2,043,428Anna Upton · Global Alliance For Tb Drug Development · U19 · FY2019 · AI
CENTER FOR RECOMBINANT GAMETE CONTRACEPTIVE VACCINOGENS
$2,041,686University Of Virginia Charlottesville · U54 · FY2000 · HD
First in Human Study of a Tau Self-Association Small Molecule Inhibitor in Healthy Volunteers
$2,039,616William A. Erhardt · Oligomerix, Inc · R01 · FY2023 · AG
Influenza vaccination using a microneedle patch
$2,026,290Mark R Prausnitz · Georgia Institute Of Technology · U01 · FY2012 · EB
PLT+ Characterization and IND-Enabling Studies
$2,022,100Dean Alan Falb · Stellular Bio, Inc. · R44 · FY2020 · HL
UTHSC RBL Administrative Supplement For Antiviral Discovery & Development
$2,021,906Colleen B Jonsson · University Of Tennessee Health Sci Ctr · G20 · FY2022 · AI
TRIP-PCI: PAR1 Pepducin-Based Interventions in Arterial Thrombosis
$2,013,904Athan Kuliopulos · Tufts Medical Center · P50 · FY2014 · HL
Salivary Gland Secretion Mechanisms During Normal And Altered Functional States
$2,012,493Bruce J Baum · National Institute Of Dental & Craniofacial Research · ZIA · FY2010 · DE
Develop an engineered Cas effector for in vivo cell-targeted delivery in the eye to treat autosomal dominant BEST disease
$2,008,538David M Gamm · University Of Wisconsin-Madison · U19 · FY2024 · NS
IGF::OT::IGF DEVELOPMENT OF AN INNOVATIVE PSMA-TARGETED RADIONUCLIDE THERAPY FOR PROSTATE CANCER. PERIOD OF PERFORMANCE: 09/30/2015 - 02/28/2018.
$2,000,000Beatrice Langton-Webster · Cancer Targeted Technology, Llc · N43 · FY2016 · CA
IGF::OT::IGF SBIR Phase II Topic 349 Quantum Dot FRET Immunoassay to Quantify Intramolecular Epitopes of Analytes in Tissue Sections
$2,000,000Adnrew Wang · Ocean Nanotech, Llc · N01 · FY2018 · CA
Core--Vector
$1,993,136Beth Israel Deaconess Medical Center · U19 · FY2005 · AI
Thin, High-Density, High-Performance, Depth and Surface Microelectrodes for Diagnosis and Treatment of Epilepsy
$1,991,906Shadi Dayeh · University Of California, San Diego · UG3 · FY2025 · NS
TRIP-PCI: PAR1 Pepducin-Based Interventions in Arterial Thrombosis
$1,975,189Athan Kuliopulos · Tufts Medical Center · P50 · FY2015 · HL
Therapeutics for inflammatory bowel disease from the microbiome
$1,973,386Sarkis K Mazmanian · Symbiotix Biotherapies, Inc. · R42 · FY2016 · DK
A Novel ENaC Blocker/Osmolyte Inhalation Solution for the Treatment of Muco-Obstructive Lung Diseases
$1,971,749Karl H Donn · Parion Sciences, Inc. · R44 · FY2025 · HL
Medicinal Chemistry Optimization of Anti-Alphaviral Leads and Elucidation of Target and Off Target Engagement
$1,971,109Jennifer E. Golden · University Of Tennessee Health Sci Ctr · U19 · FY2023 · AI
Preclinical Development of Flagellin as a Mucosal Adjuvant in Biodefense Vaccines
$1,969,516Steven B. Mizel · Wake Forest University Health Sciences · U01 · FY2007 · AI
Development of a recombinant protein vaccine for Chlamydia trachomatis
$1,959,365Toni Darville · Univ Of North Carolina Chapel Hill · U01 · FY2024 · AI
Lentivirus-based Immunogene Therapy for HIV Infection
$1,936,423Carl H. June · University Of Pennsylvania · U19 · FY2006 · AI